Patents by Inventor Eric Aboagye

Eric Aboagye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DETECTION OF COGNITIVE IMPAIRMENT IN HUMAN BRAINS FROM IMAGES
    Publication number: 20230282351
    Abstract: A computer implemented method by which digital images of the human brain can be used to diagnose or to predict cognitive impairment, such as Alzheimer's disease and other forms of cognitive impairment such as so-called prodromal Alzheimer's disease. Methods of classifying or stratifying cohorts of human subjects such as for the purpose of clinical trials and/or to assess the impact of therapies are included. In some embodiments the images comprise T1 weighted MRI images.
    Type: Application
    Filed: February 15, 2021
    Publication date: September 7, 2023
    Applicant: Imperial College Innovations Limited
    Inventors: Eric Aboagye, Marianna Inglese
  • HER2 polypeptides useful for imaging and monitoring tumors and cancers
    Patent number: 10646600
    Abstract: A method of use of an isolated polypeptide conjugated with a radionuclide, wherein the isolated polypeptide binds specifically to HER2, or a variant thereof is described. The method is for monitoring the response to HSP90 inhibition and comprises the use of the isolated polypeptide conjugated with 18F. The application also describes the use of an isolated polypeptide conjugated with 18F, wherein the isolated polypeptide binds specifically to HER2 or variants thereof, as an imaging agent to monitor uptake thereof to measure HSP90 inhibition.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: May 12, 2020
    Assignees: IMPERIAL INNOVATIONS LIMITED, GE HEALTHCARE LIMITED
    Inventors: Duncan Robert R. Hiscock, Eric Aboagye, Peter Iveson, Quang-De Nguyen, Susan Hoppmann, Sebastian Trousil, Maciej Kaliszczak, Giampaolo Tomasi
  • USE OF HER2 BINDERS
    Publication number: 20160144062
    Abstract: A method of use of an isolated polypeptide conjugated with a radionuclide, wherein the isolated polypeptide binds specifically to HER2, or a variant thereof is described. The method is for monitoring the response to HSP90 inhibition and comprises the use of the isolated polypeptide conjugated with 18F. The application also describes the use of an isolated polypeptide conjugated with 18F, wherein the isolated polypeptide binds specifically to HER2 or variants thereof, as an imaging agent to monitor uptake thereof to measure HSP90 inhibition.
    Type: Application
    Filed: June 24, 2014
    Publication date: May 26, 2016
    Inventors: Ducan Robert R. HISCOCK, Eric Aboagye, Peter IVESON, Quang-De NGUYEN, Susan HOPPMANN, Sebastian TROUSIL, Maciej KALISZCZAK, Giampaolo TOMASI
  • QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS
    Publication number: 20130116206
    Abstract: There is provided compounds of formula (I), wherein R1, R2, X1, X2, and X3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as positron emission tomography (PET) imaging agents, useful in the treatment of diseases in which inhibition of epidermal growth factor receptor tyrosine kinase activity or the inhibition of HER2 activity is desired and/or required, and useful in the treatment of cancer.
    Type: Application
    Filed: December 22, 2010
    Publication date: May 9, 2013
    Applicant: IMPERIAL INNOVATIONS LIMITED
    Inventors: Federica Pisaneschi, Alan Spivey, Graham Smith, Eric Aboagye